The House E&C Health Subcommittee Hearing on May 22 featured an extensive grilling of the leaders of FDA’s three medical products centers: CDER, CBER and CDRH. Representatives on both sides of the aisle took full advantage of their floor time to probe FDA leadership on its spending, performance and specific regulatory policies – including its recent Laboratory Developed Test final rule.
Fill out the form to read the full article.
Required *